Abstract:A series of novel polypeptide-based graft copolymer poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) (PLG-g-mPEG) was synthesized through a Steglich esterification reaction of PLG with mPEG. The structure of the copolymers was confirmed by nuclear magnetic resonance spectra (NMR) and gel permeation chromatography (GPC). MTT assay demonstrated that the PLG-g-mPEGs had good cell compatibility. The unreacted carboxyl groups of the PLG-g-mPEGs were used to complex cisplatin to form polymer-metal complex nanoparticles (CDDP/PLG-g-mPEG) for cancer therapy. The average hydrodynamic radius of the CDDP/PLG-g-mPEG nanoparticles was in the range of 14-25 nm, which was beneficial for solid tumor targeting delivery. A sustained release without initial burst was achieved for the CDDP/PLG-gmPEG nanoparticles, indicating that the COOP-loaded nanoparticles had great potential to suppress the drug release in blood circulation before the nanoparticles had arrived at targeting tumors. The CDDP/PLG-g-mPEG nanoparticles showed a much longer blood retention profile as compared with the free CDDP. This indicated that the COOP-loaded nanoparticles had much more opportunity to accumulate in tumor tissue by exerting the EPR effect. In vitro tests demonstrated that the CDOP/PLG-g-mPEG nanoparticles could inhibit the proliferation of HeLa, MCF-7 and A549 cancer cells. At equal dose (4 mg kg(-1)), the CDDP/PLG-g-mPEG nanoparticles showed comparable in vivo antitumor efficacy and significantly lower systemic toxicity as compared with free cis-Diaminedichloroplatinum (cisplatin, CDDP) in MCF-7 tumor bearing mice. These suggested that the CDDP/PLG-g-mPEG nanoparticle drug delivery system had a great potential to be used for cancer therapy.

A Cross-Linked Polymeric Micellar Delivery System for Cisplatin(iv) Complex

A Core Cross-Linked Polymeric Micellar Platium(IV) Prodrug with Enhanced Anticancer Efficiency

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

A Fully Absorbable Biomimetic Polymeric Micelle Loaded with Cisplatin As Drug Carrier for Cancer Therapy

A Reduction-Degradable Polymer Prodrug for Cisplatin Delivery: Preparation, in Vitro and in Vivo Evaluation

Poly(β-cyclodextrin)/platinum prodrug supramolecular nano system for enhanced cancer therapy: Synthesis and in vivo study

Preparation of cisplatin delivery calcium phosphate nanoparticles using poly(Pt(IV) prodrug) as the payload

Harnessing Phosphato-Platinum Bonding Induced Supramolecular Assembly for Systemic Cisplatin Delivery

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

Coordinative Double Hydrophilic All-Polyether Micelles for pH-Responsive Delivery of Cisplatin

Stepwise Encapsulation and Controlled Two-Stage Release System for Cis-Diamminediiodoplatinum

Cisplatin Crosslinked Ph-Sensitive Nanoparticles for Efficient Delivery of Doxorubicin

Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation.

Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy.

A Prodrug Strategy to Deliver Cisplatin(Iv) and Paclitaxel in Nanomicelles to Improve Efficacy and Tolerance

Thermogelling Polymer–Platinum(IV) Conjugates for Long-Term Delivery of Cisplatin

CDDP supramolecular micelles fabricated from adamantine terminated mPEG and β-cyclodextrin based seven-armed poly (L-glutamic acid)/CDDP complexes.

Dual endogenous stimuli-responsive polyplex micelles as smart two-step delivery nanocarriers for deep tumor tissue penetration and combating drug resistance of cisplatin

The Use of Polymeric Platinum(iv) Prodrugs to Deliver Multinuclear Platinum(ii) Drugs with Reduced Systemic Toxicity and Enhanced Antitumor Efficacy

Fabrication of polymer–platinum(II) complex nanomicelle from mPEG–g-α,β-poly [(N-amino acidyl)-dl-aspartamide] and cis-dichlorodiammine platinum(II) and its cytotoxicity

Polypeptide-based Combination of Paclitaxel and Cisplatin for Enhanced Chemotherapy Efficacy and Reduced Side-Effects.